221.883 -

+3.213 (+1.47%)
Range 218.000 - 222.870   (2.23%)
Open 218.200
Previous Close 218.670
Bid Price 221.770
Bid Volume 8
Ask Price 221.890
Ask Volume 49
Volume 1,939,392
Value 303,464,456
Remark -
Delayed prices. Updated at 30 Jan 2026 01:05.
Data powered by
View All Events

About AbbVie

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

There are 30 followers

Followers
14
Followers
0
Followers
0
Followers
0
Followers
1
Followers
0
Followers
0
Followers
0
Retiring
Followers
1
Followers
13
Followers
0
Followers
0
Followers
0
box
Followers
0
Followers
0
Followers
0
Followers
2
Followers
1
Followers
0
Followers
2
Followers
0
Followers
0
Followers
2
Followers
0
Followers
0
Followers
0
Followers
0
Followers
4
Followers
0
Followers
0